CHRS - Coherus BioSciences, Inc.

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
211,042
211,042
326,551
475,824
356,071
Cost of revenue
70,083
70,083
57,591
37,667
17,078
Gross profit
140,959
140,959
268,960
438,157
338,993
Operating expenses
Research development
199,358
199,358
363,105
142,759
94,188
Selling general and administrative
198,481
198,481
169,713
139,079
137,037
Total operating expenses
397,839
397,839
532,818
281,838
231,225
Operating income or loss
-256,880
-256,880
-263,858
156,319
107,768
Interest expense
32,474
32,474
22,959
21,166
17,601
Total other income/expenses net
-2,400
-2,400
-283
554
2,608
Income before tax
-291,754
-291,754
-287,100
135,707
92,775
Income tax expense
0
0
0
3,463
2,942
Income from continuing operations
-291,754
-291,754
-287,100
132,244
89,833
Net income
-291,754
-291,754
-287,100
132,244
89,833
Net income available to common shareholders
-291,754
-291,754
-287,100
132,244
89,833
Basic EPS
-
-3.76
-3.81
1.85
1.29
Diluted EPS
-
-3.76
-3.81
1.62
1.23
Basic average shares
-
77,630
75,450
71,412
69,680
Diluted average shares
-
77,630
75,450
83,492
73,186
EBITDA
-
-259,280
-264,141
156,873
110,376